Published in Genes Dev on May 01, 1998
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest (2005) 5.19
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev (1999) 3.88
Vascular calcification: pathobiology of a multifaceted disease. Circulation (2008) 3.64
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int (2008) 3.54
Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev (2005) 3.38
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Dimorphic effects of Notch signaling in bone homeostasis. Nat Med (2008) 2.82
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol (2001) 2.52
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol (2001) 2.23
Regulatory mechanisms in vascular calcification. Nat Rev Cardiol (2010) 2.22
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res (2008) 2.19
Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genet (2005) 2.19
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A (2003) 2.09
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 2.08
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A (1999) 2.04
Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant (2009) 2.02
Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol (2010) 1.95
Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol (2002) 1.88
Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A (2003) 1.87
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res (2005) 1.80
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med (2011) 1.79
Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension (2010) 1.61
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.52
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer (2007) 1.48
Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol (1999) 1.48
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J (2010) 1.46
Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res (2011) 1.46
Medial vascular calcification revisited: review and perspectives. Eur Heart J (2014) 1.44
Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 (2007) 1.44
Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther (2005) 1.43
Vascular calcification in chronic kidney disease. J Bone Miner Metab (2006) 1.42
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int (2006) 1.42
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol (2014) 1.41
Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem (2008) 1.39
Genetic variants and their interactions in the prediction of increased pre-clinical carotid atherosclerosis: the cardiovascular risk in young Finns study. PLoS Genet (2010) 1.39
Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int (2006) 1.39
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol (2002) 1.38
Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int (2003) 1.37
MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med (2004) 1.36
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol (2011) 1.34
The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci U S A (2004) 1.30
Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet (2005) 1.30
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol (2001) 1.29
Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int (2013) 1.29
Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol (2009) 1.28
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol (2013) 1.24
Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol (2014) 1.21
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int (2007) 1.19
Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int (2005) 1.18
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
Osteoporosis, osteopenia, and atherosclerotic vascular disease. Arch Med Sci (2011) 1.16
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol (2007) 1.15
Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol (2009) 1.15
Effect of race and genetics on vitamin D metabolism, bone and vascular health. Nat Rev Nephrol (2012) 1.15
miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol (2011) 1.15
Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet (2009) 1.14
Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res (2002) 1.13
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol (2010) 1.12
Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation (2012) 1.11
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int (2005) 1.11
Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem (2011) 1.11
Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A (2010) 1.11
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis. Arthritis Res Ther (2008) 1.09
Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One (2011) 1.08
RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol (2007) 1.08
c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest (2006) 1.08
The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab (2008) 1.08
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res (2000) 1.07
(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther (2011) 1.07
Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. J Am Coll Cardiol (2011) 1.06
Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther (2009) 1.06
Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface (2009) 1.06
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature (1997) 7.10
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest (1993) 4.54
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Osteopontin is expressed in human aortic valvular lesions. Circulation (1995) 4.16
Bone and haematopoietic defects in mice lacking c-fos. Nature (1993) 4.07
Genetic variability in adult bone density among inbred strains of mice. Bone (1996) 3.66
Toward a molecular understanding of skeletal development. Cell (1995) 3.55
Advances in bone biology: the osteoclast. Endocr Rev (1996) 3.03
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol (1997) 2.80
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res (1996) 2.73
Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest (1993) 2.60
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol (1996) 2.36
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb (1994) 2.31
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest (1994) 2.00
Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest (1994) 1.90
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest (1995) 1.79
A skeleton in the atherosclerosis closet. Circulation (1995) 1.69
THE FORMATION OF TRUE BONE WITH CELLULAR (RED) MARROW IN A SCLEROTIC AORTA. J Exp Med (1906) 1.51
Atherosclerotic calcification: relation to developmental osteogenesis. Am J Cardiol (1995) 1.48
Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis (1980) 1.46
Role of cytokines in bone resorption. J Cell Biochem (1993) 1.42
Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci U S A (1993) 1.33
The effects of cytokines and growth factors on osteoblastic cells. Bone (1995) 1.28
Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest (1994) 1.24
Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice. Lab Invest (1996) 1.18
Cytokines and growth factors in the regulation of bone remodeling. J Bone Miner Res (1993) 1.12
Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology (1995) 1.09
Mechanism of calcification in spontaneous aortic arteriosclerotic lesions of the rabbit. An electron microscopic study. Am J Pathol (1970) 1.07
Role of molecular regulation in vascular calcification. J Atheroscler Thromb (1996) 1.05
Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo. Endocrinology (1995) 1.04
Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids? Curr Opin Lipidol (1997) 1.02
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol (1991) 15.04
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A (2001) 11.06
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature (1988) 7.45
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell (1988) 6.75
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
The virtual hospital: a new paradigm for lifelong learning in radiology. Radiographics (1994) 4.64
Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev (1998) 4.58
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev (2000) 3.86
Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature (1997) 3.47
beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene (2006) 3.43
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
The networked multimedia textbook: distributing radiology multimedia information across the Internet. AJR Am J Roentgenol (1994) 3.35
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med (1997) 3.12
Crystal structure of a beta-catenin/Tcf complex. Cell (2000) 2.93
Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol (2002) 2.92
Assembly of a tailed bacterial virus and its genome release studied in three dimensions. Cell (1998) 2.91
A new tick-transmitted disease due to Rickettsia slovaca. Lancet (1997) 2.83
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Modulation of abscisic acid signal transduction and biosynthesis by an Sm-like protein in Arabidopsis. Dev Cell (2001) 2.66
Crystal structure of the human Pax6 paired domain-DNA complex reveals specific roles for the linker region and carboxy-terminal subdomain in DNA binding. Genes Dev (1999) 2.54
Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation (2010) 2.53
Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development (2001) 2.42
Waist-to-height ratio is the best indicator for undiagnosed type 2 diabetes. Diabet Med (2013) 2.31
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev (1997) 2.21
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20